Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Midazolam and Sufentanil for Radial Artery Cannulation
NCT05863455Completed
- Sponsor
- The Affiliated Hospital of Jiaxing University
- Start
- May 2023
- Primary completion
- Oct 2024
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Randomised, triple-blind trial of sufentanil and midazolam, sponsored by The Affiliated Hospital of Jiaxing University. Primary endpoint: Overall success rate at 1 hour. Started May 2023; status: completed.
02
Drugs
sufentanilmidazolam
Beyond the preview
Go deeper on NCT05863455.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05863455.